Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Find More News Related to Agreements
Iga Swiatek from Poland won her first Wimbledon title on July 12, 2025, beating Amanda…
Punjab, a vibrant state in northern India, is known for its colorful culture, delicious food…
Brazil and Mexico are two of the most famous and exciting countries in Latin America.…
Varanasi is one of the oldest and most spiritual cities in the world. Located on…
India is a country full of history, culture and natural beauty. Many special places in…
The Indian Army has launched Operation SHIVA 2025 to ensure the safe and smooth conduct…
![](data:image/svg+xml;charset=utf-8,<svg height="195px" width="300px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="34px" width="156px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
